PCM
TXMD icon

Penserra Capital Management’s TherapeuticsMD TXMD Stock Holding History

Penserra Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-194
Closed -$7K – 1553
2021
Q3 		$7K Buy
194
+15
+8% +$666 ﹤0.01% 1393
2021
Q2 		$10K Buy
179
+3
+2% +$182 ﹤0.01% 1275
2021
Q1 		$11K Buy
176
+35
+25% +$2.74K ﹤0.01% 1030
2020
Q4 		$8K Buy
141
+94
+200% +$6.42K ﹤0.01% 951
2020
Q3 		$3K Buy
+47
New +$3.75K ﹤0.01% 890

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Penserra Capital Management's TXMD Position: Q4 2021 in Review

Penserra Capital Management sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 194 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in TXMD in Q3 2020 and held it in 5 quarters. The position peaked at $11K in Q1 2021. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

  • Penserra Capital Management reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 194 TherapeuticsMD shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in TherapeuticsMD in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's TherapeuticsMD position peaked at $11K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.